Additionally, they include in this publication the microarray/pathway analysis of human whole blood treated with RVX-208, not just the data on hepatocytes treated with RVX-208. Again, this has already been presented by the RVX team at conferences and is nice to see in published peer reviewed form. Lastly, they did Multi-Analyte Profiling (MAP) analysis on a subset of ASSURE patients to document the beneficial effects of RVX-208 on inflammatory cytokines, adhesion molecules and markers of the acute phase response.

If you're not into reading front to back science publication, I suggest you read the abstract and the discussion. That's one 2016 publication as promised by DM. My guess is the next one will be related to the kidney function abstracts recently presented.

BearDownAZ